CNS Treatment Developer Supernus Pharma (SUPN) Lowers IPO Expectations

April 27, 2012 11:09 AM EDT
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) filed an amended registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The Company lowered its expected offering, now expecting to sell 11 million common shares are a price of $5 per share.

Supernus previously expected to sling 5,769,000 shares at an expected price range of $12 to $14 per share.

The pharma plans to list on the Nasdaq Global Market under the ticker "SUPN."

The offering is being made through Citigroup, Piper Jaffray, Cowen and Company, and Stifel Nicolaus Weisel.

Supernus is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

Piper Jaffray, Stifel, Citi, Cowen & Co

Add Your Comment